Titian Software Opens US Subsidiary and Appoints Experienced President, Michael Girardi
News Oct 05, 2007
Titian Software Ltd has announced the creation of its US subsidiary by forming Titian Software, Inc., located in Hopkinton, MA. President of the new subsidiary, Michael Girardi, has a proven track record of building sales and support operations in the life science sector.
Titian specializes in sample management software for the life science industry and its Mosaic™ software suite is already in use in six of the world’s top 20 bio-pharma companies. Clients utilize Mosaic to improve the efficiency, throughput and data integrity of sample management and preparation processes that feed vital research functions. Mr Girardi will be responsible for furthering Titian’s North American customer relationships and product penetration into markets that the company serves.
Commenting on his appointment, Girardi said “Having been involved in this sector for over 17 years, I could see the impact that Mosaic has been making and I’m particularly pleased to have the opportunity of growing and developing Titian’s presence in the US.”
Prior to joining Titian, Mr Girardi has held senior management and leadership positions with Tecan (RTP, North Carolina), REMP (Oberdiessbach, Switzerland) and Zymark Corporation (Hopkinton, Massachusetts) and earned his MBA from Boston College’s Carroll School of Management.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE